Stay updated with breaking news from Target Action Date Set. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application...
Takeda TSE4502NYSETAK and HUTCHMED China Limited NasdaqAIMHCM HKEX13 HUTCHMED today announced that the U.S. Food and Drug Administration FDA has granted priority review of the New Drug Application NDA for fruquintinib a highly selective and potent inhibitor of vascular endothelial growth factor receptors VEGFR 1 2 and 3 for the treatment of adult patients with previously treated metastatic colorectal cancer CRC.
Prescription Drug User Fee Act (PDUFA) Target Action Date Set for November 30, 2023 NDA Includes Results From the Phase 3 FRESCO-2 and FRESCO Clinical Trials Takeda (TSE:4502/NYSE:TAK) and HUTCHMED
− Prescription Drug User Fee Act (PDUFA) Target Action Date Set for November 30, 2023
/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company, today announced that the U.S. Food and...